Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition
NCT04387084Phase 1Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Aug 2020
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in skin cancer, sponsored by University of Southern California. Primary endpoints: Percentage of patients completely adhering to 3 cycles of short term fasting (STF) and Percentage of patients who develop unacceptable fasting-related toxicity. Started Aug 2020; status: active, not recruiting.
02
Conditions
skin cancer
Beyond the preview
Go deeper on NCT04387084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387084.